Cargando…
Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines
The cumulative impact of chronic inflammation in patients with inflammatory bowel diseases predisposes to the development of inflammatory bowel disease-associated colorectal cancer [IBD-CRC]. Inflammation can induce mutagenesis, and the relapsing–remitting nature of this inflammation, together with...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684457/ https://www.ncbi.nlm.nih.gov/pubmed/34111282 http://dx.doi.org/10.1093/ecco-jcc/jjab102 |
_version_ | 1784617623952031744 |
---|---|
author | Porter, Ross J Arends, Mark J Churchhouse, Antonia M D Din, Shahida |
author_facet | Porter, Ross J Arends, Mark J Churchhouse, Antonia M D Din, Shahida |
author_sort | Porter, Ross J |
collection | PubMed |
description | The cumulative impact of chronic inflammation in patients with inflammatory bowel diseases predisposes to the development of inflammatory bowel disease-associated colorectal cancer [IBD-CRC]. Inflammation can induce mutagenesis, and the relapsing–remitting nature of this inflammation, together with epithelial regeneration, may exert selective pressure accelerating carcinogenesis. The molecular pathogenesis of IBD-CRC, termed the ‘inflammation–dysplasia–carcinoma’ sequence, is well described. However, the immunopathogenesis of IBD-CRC is less well understood. The impact of novel immunosuppressive therapies, which aim to achieve deep remission, is mostly unknown. Therefore, this timely review summarizes the clinical context of IBD-CRC, outlines the molecular and immunological basis of disease pathogenesis, and considers the impact of novel biological therapies. |
format | Online Article Text |
id | pubmed-8684457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86844572021-12-20 Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines Porter, Ross J Arends, Mark J Churchhouse, Antonia M D Din, Shahida J Crohns Colitis Original Articles The cumulative impact of chronic inflammation in patients with inflammatory bowel diseases predisposes to the development of inflammatory bowel disease-associated colorectal cancer [IBD-CRC]. Inflammation can induce mutagenesis, and the relapsing–remitting nature of this inflammation, together with epithelial regeneration, may exert selective pressure accelerating carcinogenesis. The molecular pathogenesis of IBD-CRC, termed the ‘inflammation–dysplasia–carcinoma’ sequence, is well described. However, the immunopathogenesis of IBD-CRC is less well understood. The impact of novel immunosuppressive therapies, which aim to achieve deep remission, is mostly unknown. Therefore, this timely review summarizes the clinical context of IBD-CRC, outlines the molecular and immunological basis of disease pathogenesis, and considers the impact of novel biological therapies. Oxford University Press 2021-06-10 /pmc/articles/PMC8684457/ /pubmed/34111282 http://dx.doi.org/10.1093/ecco-jcc/jjab102 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Articles Porter, Ross J Arends, Mark J Churchhouse, Antonia M D Din, Shahida Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines |
title | Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines |
title_full | Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines |
title_fullStr | Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines |
title_full_unstemmed | Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines |
title_short | Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines |
title_sort | inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684457/ https://www.ncbi.nlm.nih.gov/pubmed/34111282 http://dx.doi.org/10.1093/ecco-jcc/jjab102 |
work_keys_str_mv | AT porterrossj inflammatoryboweldiseaseassociatedcolorectalcancertranslationalrisksfrommechanismstomedicines AT arendsmarkj inflammatoryboweldiseaseassociatedcolorectalcancertranslationalrisksfrommechanismstomedicines AT churchhouseantoniamd inflammatoryboweldiseaseassociatedcolorectalcancertranslationalrisksfrommechanismstomedicines AT dinshahida inflammatoryboweldiseaseassociatedcolorectalcancertranslationalrisksfrommechanismstomedicines |